Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Health-related quality of life development in IPF versus other ILD – the HILDA study

Boglárka Szentes, Phillen Maqhuzu, Michael Kreuter, Thomas Bahmer, Martin Claussen, Larissa Schwarzkopf
European Respiratory Journal 2019 54: PA4722; DOI: 10.1183/13993003.congress-2019.PA4722
Boglárka Szentes
1Hlehmholtz Zentrum München, member of DZL, Neuherberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: boglarka.szentes@helmholtz-muenchen.de
Phillen Maqhuzu
2Helmholtz Zentrum München, member of DZL, Neuherberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Kreuter
3Thoraxklinik Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Bahmer
4LungenClinic Grosshansdorf, Großhansdorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Claussen
4LungenClinic Grosshansdorf, Großhansdorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larissa Schwarzkopf
2Helmholtz Zentrum München, member of DZL, Neuherberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Interstitial lung diseases (ILD) are a heterogenous group of mainly chronic lung diseases. For idiopathic pulmonary fibrosis (IPF) a high burden of disease was recently shown. The development of health-related quality of life (HRQL) of IPF patients compared to other ILD subtypes is sparsely investigated.

Methods: We measured generic HRQL (Visual Analog Scale (VAS)) and disease-specific HRQL (King’s Brief Interstitial Lung Disease questionnaire (K-BILD) and its domains breathlessness and activities, chest symptoms, psychological impact)) for 164 ILD patients at baseline and after 12 months. Important change were operationalized via minimally important difference (MID). Next, we adjusted HRQL change for sociodemographic variables and for FVC % predicted, baseline HRQL, and comorbidity burden.

Results: 25.0% of patients had IPF, 69.5% were male, median age was 66.5, baseline ØFVC % pred was 74.9 (SD:21.1) and Ø DLCO % pred was 44.8 (SD:16.5). 24.4% IPF vs 13.8% non-IPF patients deteriorated on K-BILD more than MID, and 39.0% vs 22% on VAS. 4.9% vs 14.6% improved on K-BILD, and 26.8% vs 22.0 % on VAS more than MID. Mean change in VAS (-3.1) was same in both groups, but K-BILD change was bigger for IPF (-3.0 vs. -0.2). Change in breathlessness domain differed significantly between IPF (-7.8) and non-IPF (-0.2), but change in the chest domain (-9.0 vs -2.8), and psychological impact (-1.47 vs 0.05) did not. There were no group differences in the adjusted model.

Discussion: HRQL deteriorates over time in all ILD patients. IPF patients show a faster decline, especially for breathlessness; yet differences disappear after adjustments. Thus worsening of HRQL might be underestimated in ILD in general.

  • Idiopathic pulmonary fibrosis
  • Quality of life

Footnotes

Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4722.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2019
Previous
Back to top
Vol 54 Issue suppl 63 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Health-related quality of life development in IPF versus other ILD – the HILDA study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Health-related quality of life development in IPF versus other ILD – the HILDA study
Boglárka Szentes, Phillen Maqhuzu, Michael Kreuter, Thomas Bahmer, Martin Claussen, Larissa Schwarzkopf
European Respiratory Journal Sep 2019, 54 (suppl 63) PA4722; DOI: 10.1183/13993003.congress-2019.PA4722

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Health-related quality of life development in IPF versus other ILD – the HILDA study
Boglárka Szentes, Phillen Maqhuzu, Michael Kreuter, Thomas Bahmer, Martin Claussen, Larissa Schwarzkopf
European Respiratory Journal Sep 2019, 54 (suppl 63) PA4722; DOI: 10.1183/13993003.congress-2019.PA4722
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Diagnosis of interstitial lung diseases using eNose technology
  • Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial
  • Biomarkers of collagen formation are predictive of IPF progression and death
Show more Idiopathic interstitial pneumonias

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society